Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 5/20 | 0.38 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4059533 | 0.90 | P2RX4 (0.48) | CYP3A4ALDH1A1GRIN2BP2RX4 | |
| SCHEMBL12016623 | 0.85 | ALDH1A1 (0.39) | CYP2D6CYP2C9MEN1ALDH1A1LMNA | |
| SCHEMBL1621471 | 0.84 | CYP19A1 (0.42) | CYP3A4CYP2D6CYP2C9CYP11B1MEN1 | |
| SCHEMBL20635282 | 0.83 | CYP2D6 (0.46) | CYP3A4CYP2D6CYP2C9CYP11B1LMNA | |
| SCHEMBL23764025 | 0.81 | LMNA (0.51) | MEN1ALDH1A1LMNAKMT2ATBXAS1 | |
| SCHEMBL15464597 | 0.80 | ALDH1A1 (0.36) | CYP2D6CYP2C9ALDH1A1TBXAS1CYP24A1 | |
| SCHEMBL15465728 | 0.80 | ALDH1A1 (0.36) | CYP2D6CYP2C9ALDH1A1TBXAS1CYP24A1 | |
| SCHEMBL12467754 | 0.80 | ALDH1A1 (0.36) | CYP2D6CYP2C9ALDH1A1TBXAS1CYP24A1 | |
| SCHEMBL12016624 | 0.80 | ALDH1A1 (0.36) | CYP2D6CYP2C9ALDH1A1TBXAS1CYP24A1 | |
| SCHEMBL15435863 | 0.80 | CYP19A1 (0.49) | CYP2D6CYP2C9CYP11B1TBXAS1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144914-B2 | 3,7-diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2006-12-05 | — | — | US | disclosed |
| CN-1854138-A | 3,7-diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2006-11-01 | — | — | CN | disclosed |
| CN-1263758-C | 3, 7-diazabicyclo [3.3.0] octane and its use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2006-07-12 | — | — | CN | disclosed |
| CN-1229350-C | New azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2005-11-30 | — | — | CN | disclosed |
| EP-1360187-B1 | 3,7-DIAZABICYCLO(3.3.0)OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2005-06-22 | — | — | EP | disclosed |
| CN-1489592-A | 3, 7-diazabicyclo [3.3.0] octane and its use in the treatment of cardiac arrhythmias | — | 2004-04-14 | — | — | CN | disclosed |
| US-20040053986-A1 | 3,7-Diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2004-03-18 | — | — | US | disclosed |
| EP-1360187-A1 | 3,7-DIAZABICYCLO(3.3.0)OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2003-11-12 | — | — | EP | disclosed |
| US-6559162-B2 | Electrophysiological activity | ASTRAZENECA AB (SE) | 2003-05-06 | — | — | US | disclosed |
| EP-1244631-A1 | NEW AZABICYCLOOCTANE DERIVATIVES USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2002-10-02 | — | — | EP | disclosed |
| US-20020137766-A1 | Azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | US | disclosed |
| WO-2002060902-A1 | 3,7-DIAZABICYCLO[3.3.0]OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2002-08-08 | — | — | WO | disclosed |
| WO-2001047893-A1 | NEW AZABICYCLOOCTANE DERIVATIVES USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053986-A1 | 3,7-Diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | KCNH1, KCNH2, CACNA1E | CYP3A4 115/4885CYP2D6 71/4885CYP2C9 126/4885 |
| US-20020137766-A1 | Azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias | KCNH1, KCNH2, KCNH3 | CYP3A4 231/4885CYP2D6 69/4885CYP2C9 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.